NINDS encourages small business research grant applications to develop in-vitro assays to assess the potency of Botulinum Neurotoxin Type A. This announcement is made together with the Food and Drug Administration and is supported by 2 funding mechanisms: R41/R42 and R43/R44.
Therapeutic uses of botulinum toxin have increased steadily since its initial approval. Presently, type A neurotoxin is in widespread clinical use and its potency is assessed in a mouse model with inherent variability. The purpose of this announcement is to encourage development of new non-animal-based assays to assess the potency of botulinum neurotoxin type A.
Potential applicants should contact Dr. Danilo Tagle, program director, Neurogenetics Cluster, NINDS; telephone: 301-496-5745; email: email@example.com. For more information visit http://grants.nih.gov/grants/guide/pa-files/PA-09-178.html and http://grants.nih.gov/grants/guide/pa-files/PA-09-179.html.